SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-340437
Filing Date
2021-11-24
Accepted
2021-11-24 16:47:34
Documents
14
Period of Report
2021-11-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d179303d8k.htm   iXBRL 8-K 30515
2 EX-99.1 d179303dex991.htm EX-99.1 7040
6 GRAPHIC g179303g1124233916065.jpg GRAPHIC 2695
  Complete submission text file 0001193125-21-340437.txt   168566

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgls-20211124.xsd EX-101.SCH 2895
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20211124_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20211124_pre.xml EX-101.PRE 11410
7 EXTRACTED XBRL INSTANCE DOCUMENT d179303d8k_htm.xml XML 3365
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 211447473
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences